Aryna Sabalenka Weighs In on WTA's New Gene Testing Policy Amid Fairness Debate

Aryna Sabalenka has addressed the WTA Tour's controversial new gene testing policy, which uses SRY gene detection to define biological sex in women's professional tennis. The world No. 1 player commented on the divisive measure at the Canadian Open, where the tour announced the policy to "preserve the integrity of women's professional tennis and maintain fair competition conditions." The policy marks a shift from the WTA's previous testosterone-based approach to transgender athlete eligibility.

The Policy and Its Framework

The WTA introduced the SRY gene test as a one-off assessment tool designed to distinguish between biological females and biological males competing on the tour. The test identifies the presence or absence of the SRY gene, located on the Y chromosome and involved in male-typical sex development. The policy explicitly separates biological sex from gender identity. However, the WTA built in exceptions for athletes with Complete Androgen Insensitivity Syndrome or other disorders of gonadal development, where testosterone presence does not affect physical performance.

Currently, no known transgender women are active on the WTA Tour. The previous eligibility framework relied on testosterone concentration baselines in athletes' blood. The shift to genetic testing has generated significant discussion among players and in the broader sports community regarding how to balance inclusion with competitive fairness.

Player Responses Diverge

Coco Gauff, the two-time Grand Slam champion, offered a nuanced position during her Canadian Open match. She stated she supports both the trans community and the need for fairness in women's sports, but expressed concern that the policy discussion has "created a lot of animosity towards the trans community." Gauff acknowledged understanding the biological differences that prompted the rule change while simultaneously criticizing how some have weaponized the debate to attack marginalized groups. She also suggested the WTA "could have been more transparent" with players before announcing the policy, noting that some competitors learned about it only through public announcement.

Sabalenka, as the world's top-ranked player, has now weighed in on the topic at the same tournament, indicating varied perspectives across the professional circuit. The differing positions highlight the complexity professional tennis players face when navigating policy changes that intersect competitive integrity, biological science, and social inclusion.